EGFR and cancer: In addition, HR and/or c-NHEJ deficiency could be induced by the treatment of leukemia/solid tumors with the tyrosine kinase inhibitors (TKi) against the cancer-driven oncogenic tyrosine kinases (e.g., FLT3(ITD), JAK2(V617F), c-KIT(N822K), IGF-1R, EGFR).